DNLI250117P20000
- 1.20
- +0.60+100.00%
Denali Therapeutics Newsroom
Insider Sale: Chief Medical Officer of $DNLI (DNLI) Sells 2,907 Shares
Denali Therapeutics Receives FDA Breakthrough Therapy Designation For Tividenofusp Alfa In Treatment Of Hunter Syndrome (MPS II)
Express News | Denali Therapeutics Inc - Expects to Submit Bla for Tividenofusp Alfa in Early 2025
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Is Maintained at Overweight by JP Morgan
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks
BofA Trims Denali Therapeutics Price Target to $30, Says Weakness an Opportunity
Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its...
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
Denali Therapeutics Price Target Lowered to $32 From $35 at BTIG
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87
Denali Therapeutics (DNLI) Gets a Buy From J.P. Morgan
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Denali Therapeutics Initiated at Outperform by Baird
Denali Therapeutics Analyst Ratings
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More -- Barrons.com
Biggest Stock Movers Tuesday: NARI, DNLI, and More
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)